These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33146575)

  • 1. Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyer-Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active metabolite, 6-methoxy-2-naphthylacetic acid
    Matsumoto K; Hasegawa T; Ohara K; Kamei T; Koyanagi J; Akimoto M
    Xenobiotica; 2021 Feb; 51(2):155-166. PubMed ID: 33146575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes.
    Matsumoto K; Hasegawa T; Ohara K; Takei C; Kamei T; Koyanagi J; Takahashi T; Akimoto M
    Xenobiotica; 2020 Jul; 50(7):783-792. PubMed ID: 31855101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites.
    Nobilis M; Mikušek J; Szotáková B; Jirásko R; Holčapek M; Chamseddin C; Jira T; Kučera R; Kuneš J; Pour M
    J Pharm Biomed Anal; 2013 Jun; 80():164-72. PubMed ID: 23584048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes.
    Turpeinen M; Hofmann U; Klein K; Mürdter T; Schwab M; Zanger UM
    Drug Metab Dispos; 2009 May; 37(5):1017-24. PubMed ID: 19204080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone.
    Matsumoto K; Nemoto E; Hasegawa T; Akimoto M; Sugibayashi K
    Biol Pharm Bull; 2011; 34(5):734-9. PubMed ID: 21532165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbon-carbon bond cleavage in activation of the prodrug nabumetone.
    Varfaj F; Zulkifli SN; Park HG; Challinor VL; De Voss JJ; Ortiz de Montellano PR
    Drug Metab Dispos; 2014 May; 42(5):828-38. PubMed ID: 24584631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Baeyer-Villiger oxidation specifically catalyzed by human flavin-containing monooxygenase 5.
    Lai WG; Farah N; Moniz GA; Wong YN
    Drug Metab Dispos; 2011 Jan; 39(1):61-70. PubMed ID: 20947616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure.
    Kumpulainen H; Mähönen N; Laitinen ML; Jaurakkajärvi M; Raunio H; Juvonen RO; Vepsäläinen J; Järvinen T; Rautio J
    J Med Chem; 2006 Feb; 49(3):1207-11. PubMed ID: 16451086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baeyer-Villiger Monooxygenase FMO5 as Entry Point in Drug Metabolism.
    Fiorentini F; Romero E; Fraaije MW; Faber K; Hall M; Mattevi A
    ACS Chem Biol; 2017 Sep; 12(9):2379-2387. PubMed ID: 28783300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous analysis of naproxen, nabumetone and its major metabolite 6-methoxy-2-naphthylacetic acid in pharmaceuticals and human urine by high-performance liquid chromatography.
    Mikami E; Goto T; Ohno T; Matsumoto H; Nishida M
    J Pharm Biomed Anal; 2000 Oct; 23(5):917-25. PubMed ID: 11022916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of HSD17B12 as an enzyme catalyzing drug reduction reactions through investigation of nabumetone metabolism.
    Ichida H; Fukami T; Kudo T; Mishiro K; Takano S; Nakano M; Morinaga G; Matsui A; Ishiguro N; Nakajima M
    Arch Biochem Biophys; 2023 Mar; 736():109536. PubMed ID: 36724833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiota metabolizes nabumetone
    Jourova L; Anzenbacher P; Matuskova Z; Vecera R; Strojil J; Kolar M; Nobilis M; Hermanova P; Hudcovic T; Kozakova H; Kverka M; Anzenbacherova E
    Xenobiotica; 2019 Nov; 49(11):1296-1302. PubMed ID: 30794062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penetration of the active metabolite of nabumetone into synovial fluid and adherent tissue of patients undergoing knee joint surgery.
    Miehlke RK; Schneider S; Sörgel F; Muth P; Henschke F; Giersch KH; Münzel P
    Drugs; 1990; 40 Suppl 5():57-61. PubMed ID: 2081495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes.
    Hamman MA; Haehner-Daniels BD; Wrighton SA; Rettie AE; Hall SD
    Biochem Pharmacol; 2000 Jul; 60(1):7-17. PubMed ID: 10807940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel injection strategy of flurbiprofen axetil by inhibiting protein binding with 6-methoxy-2-naphthylacetic acid.
    Ogata K; Takamura N; Tokunaga J; Ikeda T; Setoguchi N; Tanda K; Yamasaki T; Nishio T; Kawai K
    Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):179-86. PubMed ID: 25537338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S-oxidation of S-methyl-esonarimod by flavin-containing monooxygenases in human liver microsomes.
    Ohmi N; Yoshida H; Endo H; Hasegawa M; Akimoto M; Higuchi S
    Xenobiotica; 2003 Dec; 33(12):1221-31. PubMed ID: 14742144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Determination of nabumetone and 6-methoxy-2-naphthylacetic acid in plasma using HPLC with UV and MS detection].
    Nespesná L; Stícha M; Matousková O; Perlík F; Slanar O
    Ceska Slov Farm; 2011 Feb; 60(1):17-24. PubMed ID: 21650014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms.
    Lang DH; Rettie AE
    Br J Clin Pharmacol; 2000 Oct; 50(4):311-4. PubMed ID: 11012553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [6-methoxy-2-naphthylacetic acid level in plasma, synovial fluid and adjacent tissue in patients with rheumatoid arthritis or gonarthroses after a 4-day therapy with nabumetone (Arthaxan)].
    Miehlke RK; Schneider S; Sörgel F; Muth P; Henschke F; Fedder M
    Z Rheumatol; 1991; 50(2):103-8. PubMed ID: 1872041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro.
    Skarydova L; Nobilis M; Wsól V
    Xenobiotica; 2013 Apr; 43(4):346-54. PubMed ID: 23020786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.